Business Of Biotech Deal And Investment Trends With Investment Banker David Sans
Apr 7, 2025
David Sans, an investment banker with a rich background in chemical engineering, delves into life sciences investment trends. He discusses the critical implications of patent expirations and the resulting opportunities in mergers and acquisitions. Sans highlights the evolving landscape of investments in biotech, including advancements in CAR T cell therapies and geopolitics affecting funding strategies. The conversation also explores the importance of strategic partnerships and collaborative banking, painting a hopeful picture for the future of healthcare investments.
AI Snips
Chapters
Transcript
Episode notes
Career Shift
- David Sands transitioned from Big Pharma (Novartis, Pfizer, Imclone) to life sciences investing.
- His career shift was inspired by witnessing the dynamism of the startup community and the success of Imclone Systems.
Patent Cliff Impact
- The 2010 patent cliff saw $30B in revenue lost due to patent expirations.
- The upcoming patent cliff (2025-2030) is projected to be ten times larger, creating M&A opportunities.
Cancer Moonshot Involvement
- David Sands worked on the Cancer Moonshot Initiative, a public-private partnership started in 2016.
- The initiative aimed to improve cancer outcomes, particularly for difficult-to-treat cancers like GBM.